Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Cevec Pharmaceuticals GmbH. (9/23/14). "Press Release: Cevec Introduces CMO Services for the cGMP Manufacturing of CAP-based Clinical Materials". Cologne.

Organisations Organisation Cevec Pharmaceuticals GmbH
  Group Cevec (Group)
  Organisation 2 GenIbet Biopharmaceuticals (PT)
  Group iBET – Instituto de Biologia Experimental e Tecnológica
Products Product contract manufacturing (biologicals)
  Product 2 CAP® technology (Cevec)
Persons Person Ubags, Frank (Cevec 201504– CEO before COO since 201409 before Coral BioNet + Scil Proteins + Kiadis + Rhein Biotech)
  Person 2 Kintzel, Wolfgang (Ayoxxa 201802 Managing Director + Science to Market Venture Capital + CEVEC Pharmaceuticals + Direvo)
     


CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology today announced the extension of its CAP Technology business portfolio by offering cGMP compliant Contract Manufacturing Services.

CAP-derived clinical materials comprising recombinant proteins, vaccines and gene therapy vectors are now directly available from CEVEC to support Phase I+II clinical studies.

The CAP manufacturing joint venture with Lisbon based GenIbet operates state of the art cGMP manufacturing capabilities and allows for a one-stop offer for CEVEC customers in need of preclinical and clinical development of CAP Cell-derived materials.

First CAP-based clinical material has already been produced by the GenIbet facility.

"Our vision is to become the leading independent player for human cell line based clinical materials. This is the next step in growing CEVEC along the value chain. The Contract Manufacturing business will be under the leadership of Frank Ubags, who recently joined us as COO. Frank has an impressive track record in the biopharmaceutical sector in establishing and implementing growth strategies" stated Wolfgang Kintzel, CEO at CEVEC.


About CEVEC Pharmaceuticals GmbH - www.cevec.com

CEVEC offers the human amniocyte based protein expression platform CAP for the transient and stable production of superior Biopharmaceuticals, CAP Cells are immortalized suspension cells for stable protein production developed by CEVEC. This non-tumor origin cell line exhibits high protein expression, has been adapted to serum-free suspension culture and shows post-translational modifications that are human-like, including authentic human glycosylation patterns. The technology allows for superior yields of complex (glyco-) proteins in a shorter time frame than traditional methods and has proven to be a versatile production platform for gene therapy vectors, viruses and vaccines.


Contact:
Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
phone +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
info@cevec.com
www.cevec.com

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Cevec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top